4.5 Article

Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus

期刊

CLINICAL AND EXPERIMENTAL ALLERGY
卷 39, 期 11, 页码 1700-1710

出版社

WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1365-2222.2009.03307.x

关键词

airway remodelling; asthma; budesonide; formoterol; respiratory virus

资金

  1. AstraZeneca
  2. European Society for Paediatric Infectious Diseases (ESPID)

向作者/读者索取更多资源

P>Background Rhinoviruses (RVs) are responsible for the majority of acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations. RVs infect the lower airways and induce the production of pro-inflammatory and remodelling-associated mediators. Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on virus-induced inflammation and remodelling are less known. Objective We investigated whether BUD and FORM synergize in suppressing RV-induced inflammation and remodelling in the airways. Methods In vitro models of RV infection of BEAS-2B and primary normal human bronchial epithelial (NHBE) cells were used. We assessed the effects of individual and combined drugs administered post-infection, at a clinically relevant concentration range (10-6-10-10 m), on the production of CCL5, CXCL10, CXCL8, IL-6 and the remodelling-associated VEGF and bFGF, using ELISA and RT-PCR. Results BUD effectively suppressed RV-mediated induction of all mediators studied, in a concentration-dependent manner. FORM alone suppressed the production of CXCL8 and bFGF. The combination of BUD and FORM had concentration-dependent, additive or synergistic effects in the suppression of RV-induced CCL5, CXCL8 and CXCL10 in both cell types as well as VEGF in NHBE only. Combination treatment also resulted in an enhanced suppression of RV-induced IL-6, and CCL5 at the mRNA level as compared with BUD or FORM alone. Conclusion BUD and FORM suppress RV-induced chemokines and growth factors in bronchial epithelial cells in a concentration-dependent, synergistic or additive manner. These data further support the combined use of BUD and FORM in asthma and COPD and intensification of this therapy during exacerbations. Cite this as: C. L. Skevaki, I. Christodoulou, I. S. Spyridaki, I. Tiniakou, V. Georgiou, P. Xepapadaki, D. A. Kafetzis and N. G. Papadopoulos, Clinical & Experimental Allergy, 2009 (39) 1700-1710.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据